Abstract

Background Glioblastoma (GBM) is a treatment refractory cancer of extreme unmet need which exhibits treatment resistance due to a subpopulation of GBM cancer stem cells which have constitutive DNA damage response activation driven by elevated replication stress (RS). RS response inhibition is potently cytotoxic to GSC, however mechanistic understanding will be key to biomarker discovery and successful clinical translation. Aims/Objectives We investigated response to combined ATR and PARP inhibition (CAiPi) to gain mechanistic insight and inform biomarker development. Feasibility of this approach was explored in an in vivo orthotopic GBM model. Methods/Results Responses to CAiPi in a panel of primary paired GBM GSCs vs differentiated progeny were heterogenous. CAiPi is selectively GSC cytotoxic in a subpopulation of tumours. A population of treatment-sensitive GSCs with increased numbers of 53BP1 nuclear bodies in G1 phase with CAiPi were identified, indicative of under-replication of DNA in S phase. DNA fibre analysis identified increased new origin firing with PARPi, which was correlated with increased PARP trapping. Inhibition of origin firing by exposure to roscovitine rescued the CAiPi cytotoxic phenotype, suggesting origin firing has an important role in selective GSC cytotoxicity. In vivo PK studies have demonstrated effective tumour penetration by both drugs. Conclusions Selective GSC cytotoxicity is induced by CAiPi via dysregulation of replication, by both DNA under-replication resulting in DNA lesions, and the novel finding of increased new origin firing in GSC due to PARPi. In vivo survival studies of CAiPi are planned.

Highlights

  • GSC treatment resistance is due to constitutive DNA damage response activation driven by elevated replication stress (RS)

  • We investigated response to combined ATR and PARP inhibition (CAiPi) to gain mechanistic insight, for future biomarker development and clinical translation

  • A panel of patient-derived GBM cell lines were cultured as stem enriched (GSCs) or stem depleted, to characterise response to combined ATR inhibition (VE821 5μM) and PARP inhibition (Olaparib 1μM), by CellTiter-Glo viability assay

Read more

Summary

Introduction

Glioblastoma (GBM) is a deadly cancer associated with local recurrence, driven by treatment-resistant GBM cancer stem cells (GSCs). GSC treatment resistance is due to constitutive DNA damage response activation driven by elevated replication stress (RS). GBM patient tumour immunofluorescence showed RS-marker RPA32 was significantly higher in cell populations with high GSC-marker Sox2 [1]. RS response inhibition is potently cytotoxic to GSCs We investigated response to combined ATR and PARP inhibition (CAiPi) to gain mechanistic insight, for future biomarker development and clinical translation

Methods
One important mechanism of PARPi activity is their ability to trap
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.